PepGen’s Mid-Stage Myotonic Dystrophy Study Hit With ‘Surprise’ Pause

Why It Matters

The hold highlights regulatory risk tied to pre‑clinical findings, potentially delaying a first‑in‑class therapy for DM1 and affecting PepGen’s valuation and partnership prospects.

Key Takeaways

• FDA partial hold due to mouse blood pressure data.
• PepGen’s PGN‑EDODM1 retains orphan and fast‑track status.
• International sites continue dosing despite U.S. pause.
• Phase 2 readout still slated for March.
• Shares dropped over 17% after FDA hold.

Pulse Analysis

Myotonic dystrophy type 1 (DM1) remains one of the most prevalent adult muscular dystrophies, with no disease‑modifying therapy approved to date. PepGen’s investigational oligonucleotide PGN‑EDODM1 is designed to correct the mis‑splicing of the DMPK gene by restoring normal RNA‑binding protein function, a strategy that has attracted orphan‑drug and fast‑track designations from the FDA. The Phase 2 FREEDOM2 trial, the company’s most advanced clinical effort, is intended to deliver multiple‑ascending‑dose safety and efficacy data that could position PepGen as a first‑in‑class player in the DM1 market.

The FDA’s unexpected partial clinical hold centers on a sub‑chronic mouse study that showed transient hypotension at certain infusion rates, a finding not replicated in non‑human primates or the earlier Phase 1 human cohort. Regulators flagged the pre‑clinical pharmacology and toxicology package, prompting PepGen to submit additional analyses and unblinded Phase 1 data. While the agency did not question the existing human safety dossier, the pause introduces uncertainty around the U.S. timeline, potentially delaying the March multiple‑ascending‑dose readout and adding risk to the company’s valuation.

Despite the U.S. hold, PepGen is pressing ahead in the U.K., Canada, South Korea, Australia and New Zealand, where local regulators have cleared dosing. This geographic diversification mitigates short‑term revenue risk and preserves the March data milestone, which investors will scrutinize for signals of efficacy. If the hypotension signal proves mouse‑specific, PepGen can argue for a swift FDA resolution, potentially restoring market confidence. However, the episode underscores the heightened scrutiny of pre‑clinical data in the biotech sector, reminding stakeholders that regulatory setbacks, even minor, can materially affect share price and partnership prospects.